Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Solid Biosciences to Present at Upcoming Scientific and Patient Advocacy Conferences

SLDB

CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate in the following upcoming scientific and patient advocacy conferences:

PPMD 2022 Annual Conference – June 23-26, 2022, Scottsdale, AZ
Carl Morris, Ph.D., Chief Scientific Officer at Solid Biosciences, will participate in the Gene Therapy Approaches to Replace or Restore Dystrophin session on Friday, June 24, at 11:30 a.m. EDT / 8:30 a.m. MST.

Event and registration information is available at:
https://www.parentprojectmd.org/events/ppmds-2022-annual-conference/

ICNMD 2022 | 17th International Congress on Neuromuscular Diseases – July 5-9, 2022, Brussels, BE
Perry Shieh, M.D., Ph. D. Professor of Neurology and Pediatrics at the University of California, Los Angeles, and an IGNITE DMD investigator, will participate in the PS03: Selected Abstracts for Oral Presentation session on Thursday, July 7, at 10:30 a.m. ET / 4:30 p.m. CEST.

Event and registration information is available at: https://icnmd.org/registration2022/

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001, as well as our recently announced next-generation gene therapy candidate, SGT-003. For more information, please visit www.solidbio.com.

Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com

Caitlin Lowie
Solid Biosciences
607-423-3219
CLowie@solidbio.com

Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com


Primary Logo